DE69413923D1 - Rapamycin-Zubereitungen für die intravenöse Injektion - Google Patents

Rapamycin-Zubereitungen für die intravenöse Injektion

Info

Publication number
DE69413923D1
DE69413923D1 DE69413923T DE69413923T DE69413923D1 DE 69413923 D1 DE69413923 D1 DE 69413923D1 DE 69413923 T DE69413923 T DE 69413923T DE 69413923 T DE69413923 T DE 69413923T DE 69413923 D1 DE69413923 D1 DE 69413923D1
Authority
DE
Germany
Prior art keywords
rapamycin
solution
intravenous injection
preparations
volume percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69413923T
Other languages
English (en)
Other versions
DE69413923T2 (de
Inventor
Robert Paul Waranis
Thomas Waymond Leonard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of DE69413923D1 publication Critical patent/DE69413923D1/de
Application granted granted Critical
Publication of DE69413923T2 publication Critical patent/DE69413923T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69413923T 1993-09-30 1994-09-29 Rapamycin-Zubereitungen für die intravenöse Injektion Expired - Fee Related DE69413923T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12952693A 1993-09-30 1993-09-30

Publications (2)

Publication Number Publication Date
DE69413923D1 true DE69413923D1 (de) 1998-11-19
DE69413923T2 DE69413923T2 (de) 1999-05-12

Family

ID=22440429

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69413923T Expired - Fee Related DE69413923T2 (de) 1993-09-30 1994-09-29 Rapamycin-Zubereitungen für die intravenöse Injektion

Country Status (12)

Country Link
US (1) US5616588A (de)
EP (1) EP0650729B1 (de)
KR (1) KR100376192B1 (de)
AT (1) ATE172120T1 (de)
AU (1) AU689488B2 (de)
DE (1) DE69413923T2 (de)
DK (1) DK0650729T3 (de)
ES (1) ES2123721T3 (de)
FI (1) FI944537A (de)
HK (1) HK1012230A1 (de)
HU (1) HU219236B (de)
SG (1) SG47715A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
EP1319008B1 (de) 2000-09-19 2008-10-15 Wyeth Wasserlösliche rapamycin-ester
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
CN100522967C (zh) 2002-02-01 2009-08-05 阿里亚德基因治疗公司 含磷化合物及其应用
RU2344821C2 (ru) 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
PT1539157E (pt) 2002-09-18 2013-10-04 Univ Pennsylvania Rapamicina para utilização na inibição ou prevenção de neovascularização coroidal
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
KR100562800B1 (ko) * 2004-04-26 2006-03-23 이영기 소형 전기세탁기용 탈수통 클러치장치
AU2005266449B2 (en) * 2004-07-30 2009-10-08 Novartis Ag Compound formulations of 2-amino-1,3-propanediol compounds
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
BRPI0608152A2 (pt) 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
WO2007092620A2 (en) * 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
CA2645488C (en) 2006-03-23 2014-09-02 Macusight, Inc. Formulations comprising rapamycin and methods using same for vascular permeability-related diseases or conditions
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
KR101267813B1 (ko) 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
KR102305844B1 (ko) * 2014-01-29 2021-09-28 삼성전자주식회사 세탁기 및 그 제어방법
JP7402806B2 (ja) 2018-02-23 2023-12-21 バイオトロニック アクチェンゲゼルシャフト ４０－ｏ－環状炭化水素エステル及び関連構造のための非経口製剤材料及び方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JPH0734373B2 (ja) * 1989-11-15 1995-04-12 ヒロセ電機株式会社 コネクタ
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
GB9103430D0 (en) * 1991-02-19 1991-04-03 Smithkline Beecham Plc Novel compound
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
CA2132636C (en) * 1992-03-30 2002-12-17 Robert P. Waranis Rapamycin formulation for iv injection
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection

Also Published As

Publication number Publication date
DK0650729T3 (da) 1999-06-23
EP0650729B1 (de) 1998-10-14
FI944537A0 (fi) 1994-09-29
FI944537A (fi) 1995-03-31
KR100376192B1 (ko) 2005-08-18
HUT71101A (en) 1995-11-28
AU689488B2 (en) 1998-04-02
SG47715A1 (en) 1998-04-17
HU9402808D0 (en) 1995-01-30
ES2123721T3 (es) 1999-01-16
US5616588A (en) 1997-04-01
ATE172120T1 (de) 1998-10-15
KR950007855A (ko) 1995-04-15
DE69413923T2 (de) 1999-05-12
HU219236B (en) 2001-03-28
HK1012230A1 (en) 1999-07-30
EP0650729A1 (de) 1995-05-03
AU7435394A (en) 1995-04-13

Similar Documents

Publication Publication Date Title
DE69413923D1 (de) Rapamycin-Zubereitungen für die intravenöse Injektion
DE69413921T2 (de) Rapamycin-Zubereitungen für die intravenöse Injektion
DK0633783T3 (da) Rapamycin-præparat til intravenøs injektion
DE3766175D1 (de) Pharmazeutische zusammensetzungen.
EA199600024A3 (ru) Жидкая стабильная фармацевтическая композиция, содержащая уратоксидазу и лиофилизат для её получения
HU912300D0 (en) Hydrophilic water pump spray with nitroglycerine content
BG105274A (en) Pharmaceutical composition for injection based on paracetamol
AU551407B2 (en) Crystalline human leukocyte interferon
KR870700020A (ko) 단백질 흡수증가제
TH40961A (th) สารผสมทางเภสัชกรรมที่มีดาลโฟพริสทีนและควินูพริสทีนเป็นหลักและการเตรียมสารเหล่านั้น

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WYETH (N.D.GES.D. STAATES DELAWARE), MADISON, N.J.

8339 Ceased/non-payment of the annual fee